XPS™ has received CE mark

XVIVO Perfusion has received a CE mark for its newly developed appliance for
lung perfusion, XPS™ (Xvivo Perfusion System). This enables sales of XPS™ and
the accompanying single-use products in Europe.
Since 2009, XVIVO Perfusion AB (publ) has developed a complete system to
facilitate ex vivo lung perfusion (EVLP) using STEEN Solution™. With its
integrated Hamilton C2 ventilator and MAQUET CardioHelp centrifugal pump, XPS™
is the most flexible and complete platform for EVLP on the market and it gives
the transplantation team full control of the entire process. The system’s
flexibility allows the user to choose both ventilation and perfusion strategy in
accordance with the clinic’s desired protocol.

Furthermore, the XPS™ design enables X-ray or CT scanning to be done during the
ongoing EVLP evaluation without interrupting the procedure. XPS™ has a user
-friendly graphic interface with touchscreen functionality and data capture of
the lung’s values during the entire EVLP procedure provides the basis for
analysis and evaluation before a final clinical decision to use of the organ.
XPS™ with STEEN Solution™ enables more lungs to be used for transplantation,
which means that more patients with severe lung disease are given higher quality
of life and a longer life.

XPS™ has been used with good clinical results at leading clinics in the USA
within the framework of the NOVEL study. EVLP with STEEN Solution™ has been used
in more than 300 lung transplantations at almost 30 clinics, for example in
Vienna, Paris and Toronto, and has displayed stable results there similar to
those that XVIVO Perfusion recently published from the American NOVEL study (see
press release of March 21, 2014).

“We can now meet our customers’ wishes for a flexible and safe system for EVLP.
The good clinical results and the large number of transplantations performed
using STEEN Solution™ and the Toronto method have resulted in the great interest
that we encounter among clinics in Europe,” says XVIVO Perfusion’s CEO Magnus
Nilsson.

March 31, 2014
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson
CEO
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

XVIVO Perfusion is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on March
31, 2014 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com